Marguerita (Rita) Cheng, CFP®

We were excited to host Tribe Public's Webinar Presentation and Q&A Event, which was held Tuesday, July 9 at 11:30 am ET. Eupraxia Pharmaceuticals' (NASDAQ: EPRX) Chief Executive Officer, James A. Helliwell, MD, delivered a presentation titled “Exploring The Rapid Rise Of #Osteoarthritis.” He was also be available for a 5-10 minute Q&A session at the end of the presentation. Watch this event video now" https://lnkd.in/gSxmxZqs Eupraxia is a clinical-stage #biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. The Company strives to provide improved patient benefit and has developed technology designed to deliver targeted, long-lasting activity with fewer side effects. #DiffuSphere™, a proprietary, polymer-based micro-sphere #technology, is designed to facilitate targeted #drugdelivery, with extended duration of effect, and offers multiple, highly tuneable pharmacokinetic (PK) profiles. This investigational technology can be engineered for use with multiple active pharmaceutical ingredients and delivery methods. Tribe Public LLC is a San Francisco, CA-based organization that hosts complimentary worldwide webinar & in-person meeting events in the U.S. Tribe's complimentary events focus on issues that the Tribe members care about with an emphasis on hosting management teams from publicly traded companies from all sectors & financial organizations that are seeking to increase awareness of their products, progress and plans. Tribe members primarily include Family Offices, Portfolio Managers, Registered Investment Advisors, Accredited Investors, Sell Side Analysts, and members of media. Tribe Members are encouraged to express their interest in speakers they care about and want to learn from at the Tribe Public website via the Tribe's FREE "Wish List" process. www.tribepubic.com

We're happy to share some insights from our recent #AACR poster presentation. Our CSO, Michael Newman, and CEO, Jeffrey Meckler, discuss Key findings video from Indaptus Therapeutics (NASDAQ: INDP): "Our poster not only confirmed the robust data from our preclinical animal studies, but also demonstrated similar success with #human #immunecells in the lab. There has been a long-standing misconception that bacteria can only activate the innate side of the immune system—our results clearly show activation of the #adaptive #immunesystem as well. Excitingly, our studies also revealed additive or synergistic effects when combined with the established cancer treatment, Interleukin 2 (IL-2). This suggests additional potential for our Decoy technology in combination therapies. Watch the discussion to learn more about how these findings are fueling our mission to revolutionize cancer treatment. #IndaptusTherapeutics #biotechnology #cancerresearch #Immunotherapy #Decoy20 $INDP #MichaelNewmann #JeffreyMeckler